

Sebastian Ochsenreither

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/490166/publications.pdf>

Version: 2024-02-01

25
papers

478
citations

932766

10
h-index

713013

21
g-index

26
all docs

26
docs citations

26
times ranked

743
citing authors

#	ARTICLE	IF	CITATIONS
1	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 323-335.	5.1	173
2	Extrapulmonary small cell carcinoma (EPSCC): 10 years' multi-disciplinary experience at CharitÄ©. <i>Anticancer Research</i> , 2009, 29, 3411-5.	0.5	36
3	Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis. <i>Clinical Lung Cancer</i> , 2020, 21, e607-e621.	1.1	32
4	KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (â‰¥50%) lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 737-752.	1.3	28
5	Local ablative treatment for synchronous single organ oligometastatic lung cancerâ€”A propensity score analysis of 180 patients. <i>Lung Cancer</i> , 2018, 125, 164-173.	0.9	27
6	First-In-Human Phase I Study of a Next-Generation, Oral, TGFÎ² Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6666-6676.	3.2	27
7	Support of a molecular tumour board by an evidence-based decision management system for precision oncology. <i>European Journal of Cancer</i> , 2020, 127, 41-51.	1.3	25
8	FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9510-9510.	0.8	22
9	Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. <i>Cells</i> , 2021, 10, 517.	1.8	20
10	STREAM: A randomized discontinuation, blinded, placebo-controlled phase II study of sorafenib (S) treatment of chemonaïve patients (pts) with metastatic uveal melanoma (MUM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9511-9511.	0.8	12
11	Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (â‰¥ 50%) NSCLC: Real-world Results with Special Focus on PS â‰¥ 2, Brain Metastases, and Steroids. <i>Clinical Lung Cancer</i> , 2021, 22, 411-422.	1.1	11
12	Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. <i>International Journal of Cancer</i> , 2020, 147, 2293-2302.	2.3	10
13	Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients. <i>Journal of Translational Medicine</i> , 2010, 8, 35.	1.8	9
14	Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1217-1227.	2.0	8
15	Carcinoma of Unknown Primary and the 8th Edition TNM Classification for Head and Neck Cancer. <i>Laryngoscope</i> , 2021, 131, E2534-E2542.	1.1	8
16	pN status predicts outcomes in surgically treated pT1â€“pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 2787-2795.	0.8	6
17	FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. <i>Lung Cancer</i> , 2021, 157, 66-74.	0.9	6
18	A phase I study of the bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3091-TPS3091.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Melting Point Assay for the JAK2 V617F Mutation, Comparison with Amplification Refractory Mutation System (ARMS) in Diagnostic Samples, and Implications for Daily Routine. <i>Molecular Diagnosis and Therapy</i> , 2010, 14, 185-190.	1.6	5
20	First interim analysis of the SirTac trial: A randomized phase II study of SIRT and DSM-TACE in patients with liver metastases from uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9511-9511.	0.8	4
21	Association of an APOBEC mutational signature, mutational load, and BRCAness with inflammation and PD-L1 expression in HNSCC.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14613-e14613.	0.8	2
22	Immunomodulatory effects of 5-azacytidine in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3083-3083.	0.8	1
23	Cyclin-A1 expression in acute myeloid leukemia stem cells and its representation as an immunogenic antigen that can be targeted by cytotoxic T cells.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2523-2523.	0.8	0
24	Association of methylation of homologous repair genes with expression of immune checkpoints in squamous cell carcinoma of head and neck, lung and cervix.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11543-11543.	0.8	0
25	Collecting wisdom: Creating an evidence framework for personalized cancer therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23141-e23141.	0.8	0